By Emon Reiser
Vertex Pharmaceuticals posted a double-digit increase in its quarterly revenue thanks to strong sales for its cystic-fibrosis treatment.
The biotechnology company on Monday reported a profit of $913 million, or $3.50 a share, for the fourth quarter, compared with $968.8 million, or $3.76 a share, in the same quarter a year earlier.
Adjusting for one-time items, Vertex reported earnings of $3.98 a share, below the $4.02 adjusted earnings a share that analysts polled by FactSet expected.
Revenue rose 16%, to $2.91 billion, exceeding analyst estimates of $2.78 billion. The top-line growth was primarily driven by performance of Trikafta, which treats cystic fibrosis.
For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early contributions from Journavx, a treatment for adults with moderate-to-severe acute pain.
The company also said Operating Chief Stuart Arbuckle would retire July 1 as part of a planned transition. He is credited with helping to lead the company for over 13 years. Financial Chief Charlie Wagner will assume the additional role of operating chief.
Write to Emon Reiser at emon.reiser@wsj.com
(END) Dow Jones Newswires
February 10, 2025 16:56 ET (21:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。